Need help? Our team of experienced experts is here for you with full support.
AKA-18
Crisaborole
Cat. No.
AKA-18
CAS No.
906673-24-3
MF
C14H10BNO3
MW
251.048
Crisaborole is a potent inhibitor of PDE4 and cytokine release, capable of inhibiting PDE4.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Storage and Shipping
References
Product Name
Crisaborole
CAS No.
906673-24-3
MF
C14H10BNO3
MW
251.048
Specification
99%
Research Area
Skin disease
Description
Crisaborole is a potent inhibitor of PDE4 and cytokine release, capable of inhibiting PDE4. Packing: 1kg/bag; 25kg/drum or as request Availability: In stock
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Akama T, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorganic & Medicinal Chemistry Letters. 2009 Apr 15;19(8):2129-32.
[2]. Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Current Opinion in Investigational Drugs. 2009 Nov;10(11):1236-42.
[2]. Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Current Opinion in Investigational Drugs. 2009 Nov;10(11):1236-42.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.